Treos Bio

About:

Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.

Top Investors: The Future Fund, Luminous Ventures, BXR Partners LLP

Description:

Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients.

Total Funding Amount:

$24.4M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2013-01-01

Contact Email:

info(AT)treosbio.com

Founders:

John Hautman

Number of Employees:

11-50

Last Funding Date:

2021-03-31

IPO Status:

Private

Industries: